MLchartDataset catalogue

Anagrelide hydrochloride anhydrous

Term · Oncology and biomedicine · MLC-T-ONC-010053

The hydrochloride salt of a synthetic quinazoline derivative, Anagrelide Hydrochloride reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis.

Table 1. Record
IdentifierMLC-T-ONC-010053
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010053",
  "term": "Anagrelide hydrochloride anhydrous",
  "field": "Oncology and biomedicine",
  "term_source": "Anagrelide Hydrochloride Anhydrous",
  "definition": "The hydrochloride salt of a synthetic quinazoline derivative, Anagrelide Hydrochloride reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anagrelide-hydrochloride-anhydrous/"
}

Record 1,028 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.